Table 6 Status of application of drug price calculation adjustment factors in the cost accounting method (new)
Ultra-orphan drugs | Orphan drugs | Non-orphan drugs | |
|---|---|---|---|
n = 6 | n = 7 | n = 14 | |
Premium for usefulness-based group | |||
100% | 0 | 0 | 0 |
75% | 0 | 2 | 0 |
50% | 0 | 0 | 0 |
45% | 1 | 0 | 1 |
40% | 0 | 0 | 1 |
35% | 0 | 1 | 1 |
20% | 0 | 0 | 1 |
15% | 0 | 0 | 0 |
10% | 1 | 2 | 0 |
5% | 3 | 2 | 1 |
0% | 1 | 0 | 9 |
Premium for marketability-based group | |||
10% | 6 | 7 | 0 |
5% | 0 | 0 | 2 |
0% | 0 | 0 | 12 |
Premium for Sakigake designation scheme | |||
10% | 1 | 0 | 1 |
0% | 5 | 7 | 13 |
Foreign average price adjustment | |||
100% raise | 0 | 0 | 0 |
90–99% raise | 0 | 0 | 0 |
80–89% raise | 0 | 0 | 0 |
70–79% raise | 0 | 0 | 0 |
60–69% raise | 0 | 0 | 0 |
50–59% raise | 0 | 0 | 0 |
40–49% raise | 0 | 0 | 0 |
30–39% raise | 0 | 0 | 0 |
20–29% raise | 1 | 0 | 0 |
10–19% raise | 0 | 0 | 0 |
1–9% raise | 0 | 0 | 1 |
Not applicable | 5 | 7 | 13 |
1–9% lowering | 0 | 0 | 0 |
10–19% lowering | 0 | 0 | 0 |
20–29% lowering | 0 | 0 | 0 |
30–39% lowering | 0 | 0 | 0 |
40–49% lowering | 0 | 0 | 0 |
50–59% lowering | 0 | 0 | 0 |
60–69% lowering | 0 | 0 | 0 |
70% and more lowering | 0 | 0 | 0 |